Teva Sanofi Anti-TL1A Collaboration October 2023

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Teva Pharmaceutical and Sanofi announced an exclusive collaboration for TEV-574, an anti-TL1A therapeutic, in October 2023. The presentation outlines strategic rationale, clinical program updates, and financial overview of this transformative partnership aimed at advancing innovative immunology treatments.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Teva Pharmaceutical Industries

View all →

Teva Pharmaceutical 2016-2019 Financial Outlook

investor_presentation

21 Pages

Teva Pharmaceutical PIVOT TO GROWTH Investor Presentation May 2023

investor_presentation

Similar investor_presentations from other companies

Browse all →

Novolipetsk Steel Investor Presentation — July 2018

investor_presentation

24 Pages

Novolipetsk Steel

ACG Electric Metals: Green Metals Supplier Platform 2023

investor_presentation